NEW YORK (GenomeWeb) – LexaGene announced today that it has entered an agreement with a group of underwriters led by Canaccord Genuity to purchase up to 5 million units of stock at a price of $1.00 per unit, for gross proceeds of C$5.0 million ($3.7 million).

Each unit will consist of one common share of the company and one half of one common share purchase warrant, with each share entitling the holder to acquire one share at a price of C$1.30 until June 22, 2021.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.